Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Latorzeff

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
The Lancet. Oncology|January 12, 2013
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trialGwenaelle Gravis, Karim Fizazi, Florence Joly, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2014
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)Gwenaelle Gravis, Patricia Marino, Florence Joly, et al.
European Urology|October 4, 2014
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic ModelGwenaelle Gravis, Jean-Marie Boher, Karim Fizazi, et al.
European Urology|October 28, 2017
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 TrialPernelle Lavaud, Gwenaëlle Gravis, Stéphanie Foulon, et al.
The Lancet. Oncology|March 20, 2025
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortiumAmar U Kishan, Yilun Sun, Alison C Tree, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
The Lancet. Oncology|January 12, 2013
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trialGwenaelle Gravis, Karim Fizazi, Florence Joly, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2014
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)Gwenaelle Gravis, Patricia Marino, Florence Joly, et al.
European Urology|October 4, 2014
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic ModelGwenaelle Gravis, Jean-Marie Boher, Karim Fizazi, et al.
European Urology|October 28, 2017
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 TrialPernelle Lavaud, Gwenaëlle Gravis, Stéphanie Foulon, et al.
The Lancet. Oncology|March 20, 2025
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortiumAmar U Kishan, Yilun Sun, Alison C Tree, et al.
Pageof 8